Piper Sandler Starts Obsidian Therapeutics (OBX) at Overweight

August 5, 2026 2:37 AM EDT Send to a Friend
Piper Sandler analyst Kelsey Goodwin initiates coverage on Obsidian Therapeutics (NASDAQ: OBX) with a Overweight rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login